UroGen Pharma Ltd. Sustainability Profile
UroGen Pharma Ltd., a leading biopharmaceutical company headquartered in the United States, focuses on innovative therapies for urological cancers and disorders. Founded in 2004, UroGen has made significant strides in the industry, particularly with its proprietary drug delivery technology that enhances the efficacy of existing treatments. The company’s core products include UGN-101, a novel treatment for upper tract urothelial carcinoma, and UGN-102, aimed at bladder cancer. These therapies are distinguished by their unique delivery mechanisms, which target cancer cells more effectively while minimising systemic exposure. UroGen Pharma has established a strong market position, recognised for its commitment to advancing patient care through research and development in urology. With a robust pipeline and strategic partnerships, UroGen continues to shape the future of urological treatment.
DitchCarbon Score
How does UroGen Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
UroGen Pharma Ltd.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
UroGen Pharma Ltd.'s reported carbon emissions
UroGen Pharma Ltd., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that UroGen Pharma may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, UroGen Pharma's future climate commitments will be crucial for aligning with industry standards and expectations.
How Carbon Intensive is UroGen Pharma Ltd.'s Industry?
How Carbon Intensive is UroGen Pharma Ltd.'s Location?
UroGen Pharma Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
UroGen Pharma Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
